FREDERICK, Md. and MINNEAPOLIS, Minn. — TeleRare Health™ launched a partnership today with a leading community health system in Maryland, with a focus on expanding patient access to genetic testing, diagnosis, and knowledgeable care for rare and genetics-based diseases. In the United States, a disease is considered rare if it...
Latest News
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces its financial results for the financial year ended 31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS Total Group revenue $160.1M (2021: $7.6M) commercial launch of Illuccix® drives 20x increase in revenue Highly positive top-line...
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia. ZOLAR...
MELBOURNE, Australia and INDIANAPOLIS, Ind. — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial1, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer....
MELBOURNE (Australia) and INDIANAPOLIS, Indiana — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label,...
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX) today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET). The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using...
MELBOURNE, Australia and INDIANAPOLIS — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate. Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward...
MELBOURNE, Australia — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023. Further data from...
MELBOURNE, Australia and INDIANAPOLIS, Indiana — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2. IPAX-Linz is a single-arm Phase 2...
MELBOURNE, Australia and INDIANAPOLIS, Ind. — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in...